Predictive Value of Combined CRP and INR for Intracranial Hypertension in Cerebral Venous Thrombosis

Jiahui Yan1, Manli Lu1, Zhichao Huang1

  • 1Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China.

PubMed

Insights

Cerebral venous thrombosis (CVT) patients with high C-reactive protein (CRP) or low international normalized ratio (INR) face increased intracranial hypertension (IH) risk. Combining CRP and INR offers a noninvasive method for assessing IH in CVT.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Biomarker Research

Background:

  • Intracranial hypertension (IH) is a significant indicator of severity in cerebral venous thrombosis (CVT).
  • Current gold standard for measuring intracranial pressure (ICP) involves invasive lumbar puncture.
  • There is a need for noninvasive methods to assess IH in CVT patients for early risk stratification.

Purpose of the Study:

  • To develop a noninvasive predictive model for IH in CVT patients.
  • To integrate clinical features and biomarkers for improved IH risk assessment.
  • To facilitate early risk stratification and management of CVT patients.

Main Methods:

  • Consecutive enrollment of CVT patients from January 2011 to June 2024.
  • Classification of patients into CVT-IH and CVT+IH groups based on ICP levels.
  • Logistic regression analysis using C-reactive protein (CRP) and international normalized ratio (INR) levels, categorized by ROC curves, to determine IH risk.

Main Results:

  • 157 patients were included; 61 presented with IH.
  • Elevated CRP (>5.5 g/L) or low INR (<0.99) significantly correlated with higher IH incidence.
  • A combination of high CRP and low INR increased IH risk by 9.778 times; adding CRP and INR improved IH prediction accuracy in CVT patients.

Conclusions:

  • The combined use of CRP and INR effectively predicts IH occurrence in CVT patients.
  • This biomarker combination offers a potential noninvasive approach for assessing ICP in CVT.
  • Early identification of IH risk in CVT patients can be enhanced through this noninvasive model.
Abstract

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
289
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
538